{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T12:51:34Z","timestamp":1768740694752,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2369-15-188","type":"journal-article","created":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T04:01:27Z","timestamp":1417233687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Kidney function as an underestimated factor for reduced health related quality of life in patients with Fabry disease"],"prefix":"10.1186","volume":"15","author":[{"given":"Martin","family":"Wagner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Blohm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothee","family":"Vergho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Weidemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Breunig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,29]]},"reference":[{"key":"888_CR1","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","volume":"12","author":"O Lidove","year":"2010","unstructured":"Lidove O, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, Parini R, Carvalho LR, Kampmann C, Pastores GM, Mehta A: Effects of enzyme replacement therapy in Fabry disease-a comprehensive review of the medical literature. Genet Med. 2010, 12: 668-679. 10.1097\/GIM.0b013e3181f13b75.","journal-title":"Genet Med"},{"key":"888_CR2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","volume":"8","author":"CM Eng","year":"2010","unstructured":"Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR: Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2010, 8: 539-548.","journal-title":"Genet Med"},{"key":"888_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/jmg.2005.036327","volume":"43","author":"PB Deegan","year":"2006","unstructured":"Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M: European FOS investigators: natural history of fabry disease in females in the fabry outcome survey. J Med Genet. 2006, 43: 347-352.","journal-title":"J Med Genet"},{"key":"888_CR4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","volume":"93","author":"WR Wilcox","year":"2008","unstructured":"Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP: Fabry registry: females with fabry disease frequently have major organ involvement: lessons from the fabry registry. Mol Genet Metab. 2008, 93: 112-128. 10.1016\/j.ymgme.2007.09.013.","journal-title":"Mol Genet Metab"},{"key":"888_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ: Safety and efficacy of recombinant human alpha-galactosidase A\u2013replacement therapy in Fabry\u2019s disease. N Engl J Med. 2001, 345: 9-16. 10.1056\/NEJM200107053450102.","journal-title":"N Engl J Med"},{"key":"888_CR6","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N: Sustained, long-term renal stabilization after 54\u00a0months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007, 18: 1547-1557. 10.1681\/ASN.2006080816.","journal-title":"J Am Soc Nephrol"},{"key":"888_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ, Fabry Disease Clinical Trial Study Group: Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007, 146: 77-86. 10.7326\/0003-4819-146-2-200701160-00148.","journal-title":"Ann Intern Med"},{"key":"888_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1023\/A:1015511908710","volume":"11","author":"KF Gold","year":"2002","unstructured":"Gold KF, Pastores GM, Botteman MF, Yeh JM, Sweeney S, Aliski W, Pashos CL: Quality of life of patients with Fabry disease. Qual Life Res. 2002, 11: 317-27. 10.1023\/A:1015511908710.","journal-title":"Qual Life Res"},{"key":"888_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1023\/A:1015009210639","volume":"11","author":"AH Miners","year":"2002","unstructured":"Miners AH, Holmes A, Sherr L, Jenkinson C, MacDermot KD: Assessment of health-related quality-of-life in males with Anderson\u2013Fabry disease before therapeutic intervention. Qual Life Res. 2002, 11: 127-33. 10.1023\/A:1015009210639.","journal-title":"Qual Life Res"},{"key":"888_CR10","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.2215\/CJN.04340510","volume":"5","author":"C Wanner","year":"2010","unstructured":"Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE, Serra AL, Mar\u00f3di L, Mignani R, Cianciaruso B, Vujkovac B, Lemay R, Beitner-Johnson D, Waldek S, Warnock DG: Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol. 2010, 5: 2220-2228. 10.2215\/CJN.04340510.","journal-title":"Clin J Am Soc Nephrol"},{"key":"888_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/00005650-199205001-00025","volume":"30","author":"CA McHorney","year":"1992","unstructured":"McHorney CA, Ware JE, Rogers W, Raczek AE, Lu JF: The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study. Med Care. 1992, 30: 253-265.","journal-title":"Med Care"},{"key":"888_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2215\/CJN.03890609","volume":"5","author":"E Gabbay","year":"2010","unstructured":"Gabbay E, Meyer KB, Griffith JL, Richardson MM, Miskulin DC: Temporal trends in health-related quality of life among hemodialysis patients in the United States. Clin J Am Soc Nephrol. 2010, 5: 261-267. 10.2215\/CJN.03890609.","journal-title":"Clin J Am Soc Nephrol"},{"key":"888_CR13","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1097\/GIM.0b013e3181f13a4a","volume":"12","author":"T Watt","year":"2010","unstructured":"Watt T, Burlina AP, Cazzorla C, Sch\u00f6nfeld D, Banikazemi M, Hopkin RJ, Martins AM, Sims K, Beitner-Johnson D, O\u2019Brien F, Feldt-Rasmussen U: Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. Genet Med. 2010, 12: 703-712. 10.1097\/GIM.0b013e3181f13a4a.","journal-title":"Genet Med"},{"key":"888_CR14","volume-title":"SF-36 Physical and Mental Health Summary Scales, A User\u2019s Manual","author":"J Ware","year":"1994","unstructured":"Ware J, Kosinski M, Keller SK: SF-36 Physical and Mental Health Summary Scales, A User\u2019s Manual. 1994, Booston, MA: The Health Institute"},{"key":"888_CR15","first-page":"S1","volume":"39","author":"National Kidney Foundation","year":"2002","unstructured":"National Kidney Foundation: K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002, 39: S1-S266.","journal-title":"Am J Kidney Dis"},{"key":"888_CR16","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1136\/jmg.38.11.750","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH: Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001, 38: 750-60. 10.1136\/jmg.38.11.750.","journal-title":"J Med Genet"},{"key":"888_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1742-1241.2006.01237.x","volume":"61","author":"O Lidove","year":"2007","unstructured":"Lidove O, Joly D, Barbey F, Bekri S, Alexandra JF, Peigne V, Jaussaud R, Papo T: Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int J Clin Pract. 2007, 61: 293-302. 10.1111\/j.1742-1241.2006.01237.x.","journal-title":"Int J Clin Pract"},{"key":"888_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2190\/JKFW-3WXK-QA7N-BYLN","volume":"23","author":"RP Grewal","year":"1993","unstructured":"Grewal RP: Psychiatric disorders in patients with Fabry\u2019s disease. Int J Psychiatry Med. 1993, 23: 307-12. 10.2190\/JKFW-3WXK-QA7N-BYLN.","journal-title":"Int J Psychiatry Med"},{"key":"888_CR19","volume-title":"Fabry Disease: Perspectives from 5 Years of FOS","author":"B Hoffmann","year":"2006","unstructured":"Hoffmann B: Effects of enzyme replacement therapy on pain and overall quality of life. Fabry Disease: Perspectives from 5 Years of FOS. Edited by: Mehta A, Beck M, Sunder-Plassmann G. 2006, Oxford: Oxford PharmaGenesis, Chapter 40"},{"key":"888_CR20","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/mus.10497","volume":"28","author":"R Schiffmann","year":"2003","unstructured":"Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y, Khurana RK, Brady RO: Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve. 2003, 28: 703-10. 10.1002\/mus.10497.","journal-title":"Muscle Nerve"},{"key":"888_CR21","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","volume":"34","author":"M Beck","year":"2004","unstructured":"Beck M, Ricci R, Widmer U, Dehout F, De Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A: Fabry disease: overall effects of agalsidase alfa treatment. Eur J ClinInvest. 2004, 34: 838-844. 10.1111\/j.1365-2362.2004.01424.x.","journal-title":"Eur J ClinInvest"},{"key":"888_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1136\/jmg.2004.025791","volume":"42","author":"B Hoffmann","year":"2005","unstructured":"Hoffmann B, Garcia De Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R: Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet. 2005, 42: 247-252. 10.1136\/jmg.2004.025791.","journal-title":"J Med Genet"},{"key":"888_CR23","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"YA Zarate","year":"2008","unstructured":"Zarate YA, Hopkin RJ: Fabry\u2019s disease. Lancet. 2008, 372: 1427-1435. 10.1016\/S0140-6736(08)61589-5.","journal-title":"Lancet"},{"key":"888_CR24","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0","volume":"45","author":"F Angst","year":"2001","unstructured":"Angst F, Aeschlimann A, Stucki G: Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum. 2001, 45: 384-391. 10.1002\/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0.","journal-title":"Arthritis Rheum"},{"key":"888_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","volume":"111","author":"SM Sirrs","year":"2014","unstructured":"Sirrs SM, Bichet DG, Casey R, Clarke JT, Lemoine K, Doucette S, West ML: CFDI investigators. Outcomes of patients treated through the Canadian Fabry disease initiative. Mol Genet Metab. 2014, 111: 499-506. 10.1016\/j.ymgme.2014.01.014.","journal-title":"Mol Genet Metab"},{"key":"888_CR26","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1399-0004.2011.01671.x","volume":"81","author":"U Ramaswami","year":"2012","unstructured":"Ramaswami U, Parini R, Pintos-Morell G, Kalkum G, Kampmann C, Beck M: Fabry disease in children and response to enzyme replacement therapy: results from FOS \u2013 the Fabry Outcome Survey. Clinical Genetics. 2012, 81: 485-90. 10.1111\/j.1399-0004.2011.01671.x.","journal-title":"Clinical Genetics"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-15-188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2369-15-188\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-15-188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-15-188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T07:21:29Z","timestamp":1630567289000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/1471-2369-15-188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,29]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["888"],"URL":"https:\/\/doi.org\/10.1186\/1471-2369-15-188","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,29]]},"assertion":[{"value":"26 June 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"188"}}